Drug Database
Back to search

Poland· PL-100417487

ellaOne

A ulipristal product containing ulipristalum, registered in Poland by Laboratoire HRA Pharma. The same ATC class is registered in 11 of our 19 countries.

ATC G03AD02

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedellaOneATCG03AD02REGISTER NO.PL-100417487PACKS LISTED5CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ulipristalumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ulipristal is registered in 11 of 19 countries.

Countries holding a registration under ATC G03AD02 (ulipristal), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 7 of them publish a price we can compare per daily dose
Search ulipristal products by name

Ulipristal · ATC G03AD02

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Ulipristalum
Manufacturer
Laboratoire HRA Pharma
Country
Poland (PL)
ATC code
G03AD02
ATC class
Ulipristal
Defined daily dose
30 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 5

  • gtin
    03663555001105
  • gtin
    05901878600697
  • gtin
    05909991416645
  • gtin
    05903792743498
  • gtin
    05905591994019

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

98 interactions on record for ulipristal.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ulipristal against other medicinesHow interaction checks work

Ulipristal · interactions on record

98 records

  • 2 severe
  • 77 moderate
  • 19 minor

Most severe, free to view

  • EdoxabanB01AF03severe
  • VenetoclaxL01XX52severe
  • NaldemedineA06AH05moderate
  • RifaximinA07AA11moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ulipristal in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ulipristal products

Authorised across Europe · EMA

The same active substance is authorised in 18 EEA countries. Names it is sold under:

  • Austria · Lencya, Ulipristal Acetate Hexal
  • Czechia · Ulipristal Acetate Aristo
  • Germany · Femke, Lencya
  • Denmark · Femke, Ulipristal Acetate Stada
  • Spain · Ulipristal Aristo, Ulipristal Aurovitas
  • Finland · Femke, Ulipristal Acetate Stada
  • France · Ulipristal Acetate Biogaran, Ulipristal Acétate Exeltis
  • United Kingdom (Northern Ireland) · Contrella, Ellaone
  • Greece · Boled, Elperil
  • Ireland · Ulipristal Acetate Rowex
  • Iceland · Ellaone, Ulipristal Acetate Stada
  • Italy · Evante, Lencya
  • Liechtenstein · Ellaone
  • Malta · Ecinq
  • Netherlands · Ecinq, Evante
  • Norway · Ellaone, Femke
  • Portugal · Femke, Ulipristal Aristo
  • Sweden · Ulipristal Acetate Stada

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/5be05728-ffcd-4afd-a144-2abd07806266
GET /v1/drugs/5be05728-ffcd-4afd-a144-2abd07806266?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletka powlekana",
  "source": "urpl",
  "strength": "30 mg",
  "packaging": "03663555001105 ¦ Rp ¦ EU/1/09/522/003 ¦ 131583\n1 tabl.\n05901878600697 ¦ Rp ¦ EU/1/09/522/003 ¦ Delfarma Sp. z o.o. ¦ 133839\n1 tabl.\n05909991416645 ¦ Rp ¦ EU/1/09/522/003 ¦ Pharmapoint SA ¦ 134354\n1 tabl.\n05903792743498 ¦ Rp ¦ EU/1/09/522/003 ¦ InPharm Sp. z o.o. ¦ 136938\n1 tabl.\n05905591994019 ¦ Rp ¦ EU/1/09/522/003 ¦ Allpharm Sp. z o.o. sp.k. ¦ 158882\n1 tabl.",
  "substance": "Ulipristali acetas 30 mg",
  "common_name": "Ulipristalum",
  "pl_product_id": "100417487",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about ulipristal.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console